Transcriptional signature of durable effector T cells elicited by a replication defective HCMV vaccine.
Xiaohua YeDavid J H ShihZhiqiang KuJunping HongDiane F BarrettRichard E RuppNingyan ZhangTong-Ming FuW Jim ZhengZhiqiang AnPublished in: NPJ vaccines (2024)
Human cytomegalovirus (HCMV) is a leading infectious cause of birth defects and the most common opportunistic infection that causes life-threatening diseases post-transplantation; however, an effective vaccine remains elusive. V160 is a live-attenuated replication defective HCMV vaccine that showed a 42.4% efficacy against primary HCMV infection among seronegative women in a phase 2b clinical trial. Here, we integrated the multicolor flow cytometry, longitudinal T cell receptor (TCR) sequencing, and single-cell RNA/TCR sequencing approaches to characterize the magnitude, phenotype, and functional quality of human T cell responses to V160. We demonstrated that V160 de novo induces IE-1 and pp65 specific durable polyfunctional effector CD8 T cells that are comparable to those induced by natural HCMV infection. We identified a variety of V160-responsive T cell clones which exhibit distinctive "transient" and "durable" expansion kinetics, and revealed a transcriptional signature that marks durable CD8 T cells post-vaccination. Our study enhances the understanding of human T-cell immune responses to V160 vaccination.
Keyphrases
- single cell
- endothelial cells
- flow cytometry
- clinical trial
- regulatory t cells
- immune response
- induced pluripotent stem cells
- dendritic cells
- rna seq
- transcription factor
- stem cells
- metabolic syndrome
- open label
- polycystic ovary syndrome
- quality improvement
- brain injury
- mesenchymal stem cells
- epstein barr virus
- study protocol
- skeletal muscle
- drug delivery
- preterm birth
- subarachnoid hemorrhage
- cerebral ischemia